Literature DB >> 7238237

Resected ovarian recurrence from colorectal adenocarcinoma: a study of 13 cases.

S L Blamey, F T McDermott, E Pihl, E S Hughes.   

Abstract

Thirteen (1.4 per cent) of 882 female patients managed by resection for primary colorectal adenocarcinoma subsequently required for operation for ovarian recurrence. The clinical, pathologic and survival data of this group have been analyzed. Their age (mean +/- s.d., 51.2 +/- 8.4 years) was less (P = 0.004) than that of the total series of female patients (59.4 +/- 13.0 years). Survival varied from 15 to 96 months (mean 17 months) from the ovarian operation. Three patients were still alive with no evidence of recurrence at the time of the review. The low incidence of ovarian recurrence requiring operation does not support recommendations for prophylactic oophorectomy in all patients.

Entities:  

Mesh:

Year:  1981        PMID: 7238237     DOI: 10.1007/bf02641876

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  4 in total

1.  Oophorectomy in primary colorectal cancer.

Authors:  A Schofield; J Pitt; G Biring; P M Dawson
Journal:  Ann R Coll Surg Engl       Date:  2001-03       Impact factor: 1.891

2.  Ovarian metastases in young women with colorectal cancer: a retrospective multicenter cohort study.

Authors:  R van der Meer; C Bakkers; J A Wegdam; T Lettinga; E G Boerma; F Aarts; I H J T de Hingh; R M H Roumen
Journal:  Int J Colorectal Dis       Date:  2022-07-20       Impact factor: 2.796

3.  Oophorectomy and colon cancer. Impact on survival.

Authors:  G H Ballantyne; M M Reigel; B G Wolff; D M Ilstrup
Journal:  Ann Surg       Date:  1985-08       Impact factor: 12.969

4.  Bilateral ovarian micrometastatic adenocarcinoma upon prophylactic oophorectomy concurrent with low anterior resection for rectal cancer.

Authors:  Robin Irons; Erin McIntosh; Alexandre Hageboutros; David Warshal; Steven McClane
Journal:  World J Surg Oncol       Date:  2017-02-07       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.